Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Modupe Idowu

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Biomed Research International|February 7, 2023
Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview StudyClark Brown, Modupe Idowu, Richard Drachtman, et al.
Blood|January 15, 2015
Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activityKaiqi Sun, Yujin Zhang, Mikhail V Bogdanov, et al.
Blood Advances|April 19, 2024
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell diseaseSantosh L Saraf, Robert Hagar, Modupe Idowu, et al.
Blood Advances|August 12, 2018
Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell diseaseHong Liu, Morayo Adebiyi, Rong Rong Liu, et al.
Scientific Reports|July 21, 2016
Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell diseaseHongyu Wu, Mikhail Bogdanov, Yujin Zhang, et al.
British Journal of Haematology|October 6, 2021
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab studyDarla K Liles, Nirmish R Shah, Brigid Scullin, et al.
The Journal of Clinical Investigation|May 20, 2014
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progressionYujin Zhang, Vladimir Berka, Anren Song, et al.
Scientific Reports|November 12, 2017
Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell DiseaseKaiqi Sun, Angelo D'Alessandro, Mostafa H Ahmed, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Biomed Research International|February 7, 2023
Patient-Reported Experiences in Voxelotor-Treated Children and Adults with Sickle Cell Disease: A Semistructured Interview StudyClark Brown, Modupe Idowu, Richard Drachtman, et al.
Blood|January 15, 2015
Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activityKaiqi Sun, Yujin Zhang, Mikhail V Bogdanov, et al.
Blood Advances|April 19, 2024
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell diseaseSantosh L Saraf, Robert Hagar, Modupe Idowu, et al.
Blood Advances|August 12, 2018
Elevated ecto-5'-nucleotidase: a missing pathogenic factor and new therapeutic target for sickle cell diseaseHong Liu, Morayo Adebiyi, Rong Rong Liu, et al.
Scientific Reports|July 21, 2016
Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for sickle cell diseaseHongyu Wu, Mikhail Bogdanov, Yujin Zhang, et al.
British Journal of Haematology|October 6, 2021
Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab studyDarla K Liles, Nirmish R Shah, Brigid Scullin, et al.
The Journal of Clinical Investigation|May 20, 2014
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progressionYujin Zhang, Vladimir Berka, Anren Song, et al.
Scientific Reports|November 12, 2017
Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell DiseaseKaiqi Sun, Angelo D'Alessandro, Mostafa H Ahmed, et al.
The Lancet. Haematology|December 7, 2024
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trialModupe Idowu, Lucas Otieno, Bogdan Dumitriu, et al.
Pageof 3